FIGURE LEGENDS
Figure 1. Study design. Abbreviation: PK, pharmacokinetics; PD,
pharmacodynamic; OGTT, oral glucose tolerance test; EVO, evogliptin 5 mg
once daily; GLI, glimepiride 4 mg once daily; EVO+GLI, evogliptin 5 mg +
glimepiridpe 4 mg once daily
Figure 2. Mean plasma evogliptin and glimepiride
concentration-time profiles at steady-state after EVO, GLI or EVO+GLI.
Error bars represent standard deviations. (a) evogliptin, linear scale,
(b) evogliptin, semilog scale, (c) glimepiride, linear scale, (d)
glimepiride, semilog scale.
Figure 3. Mean (a) Δ serum glucose and (b) Δ serum insulin
level-time profiles at steady-state after EVO, GLI after EVO+GLI. The Δ
glucose and Δ insulin were calculated by subtracting the values at 0h
from the values at each timepoint. The Error bars represent standard
deviations.
Supplementary figure 1. Mean plasma (a) evogliptin M7, (b)
evogliptin M8 and (c) glimepiride M1 concentration-time profiles at
steady-state after EVO, GLI or EVO+GLI. Error bars represent standard
deviations.